Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.

Journal of thrombosis and haemostasis : JTH - 1 Apr 2007

De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G

Abstract excerpt

BACKGROUND: Thrombosis of splanchnic or cerebral veins is a typical manifestation of polycythemia vera (PV) or essential thrombocythemia (ET). The recently identified Janus kinase 2 (JAK2) V617F somatic mutation is closely related to chronic myeloproliferative disorders (CMD). OBJECTIVE: To assess the incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis with or without...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Polycythemia Vera

Share to Thrombocythemia, Essential

Share to Venous Thrombosis

Source

Identifiers

PMID: 17263783
DOI: 10.1111/j.1538-7836.2007.02424.x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.PMID 17263783Read ↗

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.Semantic proximity Read ↗

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.Semantic proximity Read ↗

JAK2 mutations across a spectrum of venous thrombosis cases.Semantic proximity Read ↗

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?Semantic proximity Read ↗

The JAK2 V617F mutation in patients with cerebral venous thrombosis.Semantic proximity Read ↗

Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.Semantic proximity Read ↗

The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.Semantic proximity Read ↗

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?Semantic proximity Read ↗

JAK2V617F mutation in patients with splanchnic vein thrombosis.Semantic proximity Read ↗

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?Semantic proximity Read ↗

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.Semantic proximity Read ↗

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.